ArticleBMC cancer2024

Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.

Jing Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.